Ceritinib Linked With Greater Overall, Progression-free Survival for Patients With NSCLC

Share this content:
Ceritinib may prolong overall survival (OS) and progression-free survival (PFS), in contrast with crizotinib in ALK+ non-small cell lung cancer.
Ceritinib may prolong overall survival (OS) and progression-free survival (PFS), in contrast with crizotinib in ALK+ non-small cell lung cancer.

Ceritinib may prolong overall survival (OS) and progression-free survival (PFS), in contrast with crizotinib, when used as initial anaplastic lymphoma kinase (ALK)-targeted therapy for patients with previously treated ALK+ non-small cell lung cancer (NSCLC), according to a study published in the Journal of Thoracic Oncology.1

Researchers led by Daniel Shao-Weng Tan, MD, of the National Cancer Centre, Singapore, collected data from 198 patients treated with ceritinib and 557 who were treated with crizotinib, as part of 2 single-arm ASCEND-1 and ASCEND-3 trials.

Average baseline characteristics were matched using propensity score weighting to adjust for cross-trial differences.

RELATED: Minocycline May Improve Treatment-related Fatigue in Patients With NSCLC

It was found that ceritinib was associated with longer OS and PFS, in contrast with crizotinib, upon Cox proportional hazards models. Twelve-month OS was found to be 82.6% with ceritinib and 66% with crizotinib upon Kaplan-Meier analysis.

No significant differences were found in overall response rates between the 2 groups.

Reference

  1. Tan DS, Araujo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, et al. Comparative Efficacy of Ceritinib and Crizotinib as Initial Anaplastic Lymphoma Kinase-targeted Therapies in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: an Adjusted Comparison to External Controls. [published online ahead of print June 8, 2016.] ‎J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.05.029

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters